Prof. Dr. Klaus Überla

Further involvements

• 28/03/2023

  • Poster
  • P 001

  Population-based study of the durability of humoral immunity after SARS-CoV-2 infection

   Adaptive immunity
• 28/03/2023

  • Poster
  • P 235

  Heterologous SARS-CoV-2 delta breakthrough infection elicits broader and more durable neutralizing antibody response than (non-breakthrough) infection

   Epidemiology and public health, SARS-CoV-2
• 28/03/2023

  • Poster
  • P 135

  Higher infection risk among health care workers and lower risk among smokers persistent across SARS-CoV-2 waves – longitudinal results from the population-based TiKoCo seroprevalence study

   Epidemiology and public health, SARS-CoV-2
• 28/03/2023

  • Poster
  • P 314

  Requirements for heterologous T cell help against HIV-1 in humans

   Adaptive immunity, Vaccines
• 29/03/2023

  14:45 – 15:00 12 Min. 3 Min.

  • Abstract Talk
  • O 072

  Long-lasting antibody delivery by a myotropic Adeno-Associated Virus (AAV) capsid variant – high serum levels, favourable glycosylation profile and protection from SARS-CoV-2 challenge

   SARS-CoV-2, Viral vectors and gene therapy